Press Release: Novartis and Medicines for Malaria -2-

References

1. World malaria report 2023 (who.int)

https://www.who.int/teams/global-malaria-programme/reports/world-malaria-report-2023

2. WHO guidelines for malaria - 16 October 2023 (magicapp.org)

https://app.magicapp.org/#/guideline/LwRMXj/section/j2KlbL

# # #

Novartis Media Relations

E-mail: media.relations@novartis.com

Central North America

Richard Jarvis +41 79 584 2326 Michael Meo +1 862 274 5414

Anja von Treskow +41 79 392 9697 Marlena Abdinoor +1 617 335 9525

Anna Schäfers +41 79 801 7267

Switzerland

Satoshi Sugimoto +41 79 619 2035

Novartis Investor Relations

Central investor relations line: +41 61 324 7944

E-mail: investor.relations@novartis.com

Central North America

Isabella Zinck +41 61 324 7188 Sloan Simpson +1 862 345 4440

Nicole Zinsli-Somm +41 61 324 3809 Jonathan Graham +1 201 602 9921

Imke Kappes +41 61 324 8269 Parag Mahanti +1 973 876 4912

(END) Dow Jones Newswires

April 24, 2024 00:30 ET (04:30 GMT)